RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Regenerative Medicine Advanced Therapy (United States), Conditional marketing approval (Australia), Fast Track (United States)

Clinical Trials associated with Lifileucel

NCT07288073

/ RecruitingPhase 2IIT

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

The purpose of this research study is to test the safety and effectiveness of a tumor-infiltrating lymphocyte (TIL) cellular therapy, also called LN-145 or lifileucel, and chemotherapy in combination with Interleukin-2 (IL-2) to find out what effects, if any, the combination has on participants with Cutaneous squamous cell carcinoma (CSCC) or Merkel Cell Carcinoma (MCC) who were previously treated with immunotherapy.
The names of the study interventions involved in this study are:
* Tumor Infiltrating Lymphocytes (a type of cellular therapy)
* Fludarabine and Cyclophosphamide (types of standard of care chemotherapy drugs)
* Interleukin-2 (a type of recombinant, human glycoprotein)

Start Date10 Feb 2026

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT07288203

/ Active, not recruitingPhase 2

A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma

Start Date28 Nov 2025

Sponsor / Collaborator

Iovance Biotherapeutics, Inc.

CTIS2025-522427-10-00

/ Not yet recruitingPhase 2IIT

A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study

Start Date01 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lifileucel

100 Translational Medicine associated with Lifileucel

100 Patents (Medical) associated with Lifileucel

Literatures (Medical) associated with Lifileucel

05 Jun 2026·BRITISH JOURNAL OF CANCER

Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?

Review

Author: Lorigan, Paul ; Oudit, Deemesh ; Abdulgawad, Ahmed ; Lim, Kok Haw Jonathan ; Thistlethwaite, Fiona ; Woodford, Rachel

Abstract:

Tumour infiltrating lymphocyte (TIL) therapy offers the potential for durable clinical benefit in select patients with advanced melanoma, especially after progression on treatment with immune checkpoint inhibitors and/or targeted therapies. The 2024 FDA approval of Lifileucel (Amtagvi), a commercially manufactured autologous TIL product, marks a key milestone in integrating advanced therapy medicinal products (ATMPs) into routine care for solid tumours. Health Canada has since approved Lifileucel, with regulatory and funding decisions across the UK and Europe still pending. In this Perspective, we review the evidence base and outline key considerations for national adoption of TIL therapy. Despite promising results from clinical trials, TIL therapy requires complex coordination, including patient selection, tumour procurement, manufacturing logistics, lymphodepletion, and IL-2 administration; all contingent on specialised infrastructure and well-considered integrated care pathways. While commercial centralisation may ease logistical barriers, the high cost of TIL therapy necessitates careful health economic evaluation. A nationally coordinated effort is required to harmonise clinical prioritisation strategies, maintain oversight by multidisciplinary specialist tumour boards, and consider investment in future-proof decentralised manufacturing capacity. Collaborations and peer support such as through the Advanced Therapy Treatment Centre (ATTC) Network will facilitate phased, experience-led rollout with equity-focused service design.

08 May 2026·Reviews on Recent Clinical Trials

Lifileucel: Shedding Light on a New Treatment for Advanced Melanoma

Article

Author: Corona, Kelli ; Ashchi, Andrew ; Carpenter, Lauren ; Valdes, Andres ; Ashchi Lachapelle, Andrea ; Kumar, Ashish ; Genovese, Ariana ; Huston, Jessica

Lifileucel is a tumor-derived autologous T cell therapy approved for unresectable or metastatic melanoma in adults. This article discusses 10 clinical studies on lifileucel for the treatment of advanced melanoma. The phase II study data available evaluated the safety and efficacy of lifileucel in a global, multicenter study involving adult patients with unresectable or metastatic melanoma who had previously received systemic therapies, including a PD-1 blocking antibody and, if applicable, BRAF and MEK inhibitors. Among 73 patients treated with the recommended dose, the objective response rate was 31.5%, with 4.1% achieving a complete response and 27.4% a partial response. Of the responders, 56.5%, 47.8%, and 43.5% maintained their responses without progression or death at 6, 9, and 12 months, respectively. The most common adverse events seen in clinical studies include thrombocytopenia, anemia, and febrile neutropenia. Additional studies are underway to provide further data on the use of lifileucel as a safe and effective intravenous treatment option for unresectable or metastatic melanoma. This article reviews the published data encompassing the preliminary development, pharmacology, efficacy, and safety of lifileucel.

01 May 2026·Lancet Regional Health-Europe

Advances in cell therapy for solid tumours: European perspective and future directions

Review

Author: Haanen, John B A G ; Tak, Willemijn S ; Thistlethwaite, Fiona ; Yarza, Ramón ; Lim, Kok Haw Jonathan ; Moreno, Victor

Cell therapy has revolutionised the landscape of cancer treatment, with therapies such as Chimeric Antigen Receptor T cells (CAR-T cells), showing remarkable efficacy in haematological malignancies, and approaches such as Tumour Infiltrating Lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) showing increasing promise in solid tumours. The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology. Europe has played a central role in these advances, leading pivotal phase 3 trials and pioneering hospital-exemption-based manufacturing programmes. However, the continent still faces major challenges, including fragmented regulatory frameworks, high manufacturing costs, and inequitable patient access across member states. Emerging innovations such as gene-edited, allogeneic, and iPSC-derived cell products promise to address current limitations by improving scalability, safety, and time-to-treatment. This Series paper examines the latest advancements in cell therapy, focussing on the European experience, while comparing global trends. We discuss challenges specific to Europe, such as regulatory frameworks, manufacturing scalability, and disparities in access. Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.

179

News (Medical) associated with Lifileucel

09 Jun 2026

·www.biospace.com

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi® (li ), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. Amtagvi is indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. “This approval in Australia is our third marketing authorization for Amtagvi and marks a significant step forward for Iovance in the country with the highest rate of melanoma globally,” said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President of Iovance. “We are in the process of authorizing our first Australian treatment center as we advance our expansion strategy for Amtagvi in additional markets with a high prevalence of advanced melanoma.” Australia has the highest rate of melanoma globally, with an estimated 17,000 new cases diagnosed each year and more than 1,500 deaths annually. 1,2 Similar to the U.S. and other global markets, there is a significant need for new therapies for patients with advanced melanoma. TGA granted approval based on safety and efficacy results from the global, multicenter C-144-01 trial investigating Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 therapy and targeted therapy, if applicable. About the C-144-01 Clinical Trial C-144-01 is a global, multicenter Phase 2 study in which patients received li monotherapy. The study enrolled patients with metastatic melanoma who were previously treated with at least one systemic therapy, including a PD-1 blocking antibody, and, if BRAF V600 mutation positive, a BRAF inhibitor or a BRAF inhibitor with a MEK inhibitor. Efficacy was established on the basis of objective response rate (ORR) and duration of response (DOR) by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The detailed results of C-144-01 were published in the Journal for ImmunoTherapy of Cancer in 2022. A five-year analysis of C-144-01 was published in the Journal of Clinical Oncology in 2025. Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904) , as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi ® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. 1. Cancer Australia, Melanoma of the Skin Statistics, (Accessed March 2026) 2. Melanoma Institute Australia, Melanoma Facts, (Accessed March 2026) Forward-Looking Statements Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the acceptance by the market of our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our Iovance Cell Therapy Center facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial launch; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with regulatory authorities may support registrational studies and subsequent approvals by regulatory authorities, including the risk that the planned registrational trial in advanced sarcomas may not support approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of authorized treatment centers, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS Investors IR@iovance.com 650-260-7120 ext. 150 Media PR@iovance.com 650-260-7120 ext. 150

03 Jun 2026

·allsci.com

Replimune to resubmit BLA for oncolytic IO therapy Rp1 in melanoma after FDA alignment

Massachusetts-based Replimune Group (Nasdaq: REPL) has announced plans to resubmit a Biologics License Application (BLA) to the US FDA for Rp1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 based therapy. The resubmission, described as imminent, follows what the company characterized as productive dialogue with the agency and represents a renewed attempt to secure approval for an oncolytic immunotherapy in a patient population with limited post-checkpoint options. The BLA resubmission covers Rp1 used in combination with Bristol Myers Squibb’s PD-1 inhibitor nivolumab, targeting patients with advanced melanoma who have confirmed progression on an anti-PD-1 containing regimen. Replimune said the FDA has indicated it will treat the resubmission as an urgent matter upon receipt and will prioritize its review, citing the significant unmet need in this patient population. No specific PDUFA date has been disclosed, though the expedited handling suggests a compressed review timeline relative to standard processes. The company said the resubmission would be filed within days of the May 29 announcement. The BLA is supported by data from the IGNYTE clinical trial, which evaluated Rp1 combined with nivolumab in patients with advanced melanoma who had documented progression on an anti-PD-1 containing regimen. The trial enrolled a population with limited remaining treatment options, and results from IGNYTE formed the primary evidentiary basis for the original BLA submission. Specific response rate data and durability outcomes were not reiterated in the May 29 announcement, but the FDA’s willingness to engage on a resubmission path and its stated intent to prioritize review suggests the agency views the clinical dataset as potentially actionable. Rp1 is engineered from a proprietary herpes simplex virus strain and is designed to selectively replicate within and kill tumor cells while simultaneously stimulating a systemic anti-tumor immune response. The construct incorporates a fusogenic protein (GALV-GP R⁻) and GM-CSF, intended to enhance immunogenic cell death and broaden immune activation beyond the injected lesion. This mechanism differentiates it from standard checkpoint inhibition by attempting to convert immunologically “cold” tumors into ones more responsive to immune attack. The advanced melanoma post-checkpoint space remains competitive. Approved options in this setting include tumor-infiltrating lymphocyte therapy lifileucel (Amtagvi), which received FDA approval in 2024 as the first TIL therapy for unresectable or metastatic melanoma after prior checkpoint inhibitor therapy. Rp1’s intratumoral, combination approach using an off-the-shelf oncolytic virus contrasts with the individualized, cell-based manufacturing required for TIL therapy, potentially offering logistical and accessibility advantages if approved. Approximately 8,500 patients in the US die annually from advanced melanoma, and roughly half of those receiving standard checkpoint inhibitor therapy fail to respond or subsequently progress, according to figures cited by Replimune. That residual population represents the target for Rp1, and the FDA’s acknowledgment of urgent unmet need in this group appears to have shaped the agency’s approach to the resubmission process. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

01 Jun 2026

·www.globenewswire.com

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

AUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on leveraging platform technologies that may support multiple therapeutic applications across oncology and rare disease markets rather than relying solely on a single drug candidate. Oncotelic is one of several companies, including Northwest Biotherapeutics Inc. (OTCQB: NWBO), Sangamo Therapeutics Inc. (OTCQB: SGMO), HIVE Digital Technologies Ltd. (NASDAQ: HIVE) and Iovance Biotherapeutics Inc. (NASDAQ: IOVA), that are building scalable platforms — whether cancer immunotherapy, genomic medicine, AI/data infrastructure or cell therapy — rather than single-product biotechnology stories alone. Biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics. Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance.Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics.Oncotelic Therapeutics is pursuing an integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative.Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications. Click here to view the custom infographic of the Oncotelic Therapeutics editorial. Reinventing Established Oncology Treatments The global oncology/cancer drugs market size was valued at $167 billion in 2023 and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033. Major factors driving the market growth include the rising prevalence of cancer globally and advancements in targeted therapies and immunotherapies, which offer more precise and effective treatment options. However, bringing entirely new oncology therapies to market often requires years of clinical development, substantial capital investment and high regulatory risk. As a result, biotechnology companies are increasingly exploring alternative strategies focused on improving the performance of already-approved therapeutics. Rather than developing completely new molecular entities, many companies are evaluating advanced delivery technologies that may enhance how existing drugs are absorbed, distributed and tolerated within the body. This shift is helping fuel broader industry interest in delivery-focused platform technologies that may offer faster development timelines and lower commercialization risk. The challenge of therapeutic delivery remains significant across oncology. Many targeted cancer therapies encounter limitations involving inconsistent delivery, drug resistance and difficulty achieving optimal exposure within tumor tissues. Improving delivery efficiency and systemic consistency therefore continues to represent a major area of innovation across modern cancer treatment. The challenge of therapeutic delivery remains significant across oncology. Researchers continue to face major obstacles involving drug penetration, tumor targeting, therapeutic resistance and achieving consistent exposure within tumor tissues. Studies indicate that nanoparticle and targeted drug-delivery technologies are increasingly being explored to improve pharmacokinetics, tumor accumulation and therapeutic efficacy in cancer treatment. Additional analysis notes that resistance mechanisms and delivery limitations remain major challenges across modern oncology therapeutics, contributing to continued interest in advanced drug-delivery innovation. Oncotelic Therapeutics is participating in this evolving landscape through development of Sapu003 and the company’s Deciparticle platform. Rather than focusing exclusively on discovering entirely new compounds, the company is exploring how advanced nanotechnology-enabled delivery systems and pharmacokinetic optimization may improve the clinical utility of established therapies. This approach aligns with growing industry recognition that enhancing delivery performance may create meaningful therapeutic and commercial value. Improving Exposure and Dosing Precision Bioavailability and dosing consistency remain central challenges across many oncology therapies, particularly in oral drug formulations. Variability in absorption, metabolism and systemic exposure can significantly influence efficacy, tolerability and patient outcomes. These challenges become even more important in targeted therapies that require consistent therapeutic exposure to maintain clinical effectiveness. The mTOR inhibitor everolimus illustrates some of these broader pharmacokinetic considerations. According to the National Cancer Institute, mTOR inhibitors play important roles in treating several cancers and rare diseases, yet therapeutic management often involves careful dosing oversight and pharmacokinetic considerations. The U.S. Food and Drug Administration (“FDA”) prescribing information for Afinitor(R) (everolimus) similarly highlights factors affecting systemic exposure and absorption variability. This growing focus on precision pharmacokinetics is contributing to broader interest in intravenous reformulations and delivery-engineering technologies designed to improve therapeutic consistency. According to MarketsandMarkets, the global drug-delivery systems market is expected to experience substantial long-term growth as pharmaceutical developers pursue technologies that may improve targeting precision, controlled release and bioavailability. Within this environment, Oncotelic Therapeutics is advancing delivery-focused technologies intended to potentially improve exposure consistency and therapeutic performance. Through Deciparticle and Sapu003, the company is participating in broader industry efforts centered on optimizing pharmacokinetics and improving the clinical utility of oncology therapies. This strategy reflects increasing recognition that delivery engineering itself may become a critical differentiator in future oncology treatment models. Nanotechnology Expands Therapeutic Possibilities Nanotechnology-enabled drug delivery has emerged as one of the fastest-growing segments within oncology therapeutics. Nanoparticle delivery systems are being explored for their potential to improve tissue targeting, enhance systemic stability and increase intracellular drug delivery while reducing toxicity and off-target exposure. These capabilities have attracted significant interest from both researchers and investors as oncology treatment strategies become increasingly precision-focused. According to Nature Reviews Drug Discovery, nanoparticle drug-delivery technologies may improve therapeutic efficacy by enhancing tumor penetration, controlling drug release and optimizing pharmacokinetics. Researchers continue investigating how nanotechnology can potentially overcome delivery barriers that limit many conventional therapies, including inconsistent absorption and reduced bioavailability associated with oral administration. Commercial momentum surrounding nanomedicine also continues expanding rapidly. Grand View Research projects significant growth across the global nanomedicine market, forecast to increase from $190 billion in 2023 to reach more than $410 billion in 2030, as pharmaceutical companies increasingly adopt advanced delivery systems for oncology, rare diseases and targeted therapeutics. Intravenous reformulations and nanoparticle-based delivery systems are becoming particularly important as companies seek to improve therapeutic precision and consistency. Oncotelic Therapeutics is positioning itself within this growing trend through development of its Deciparticle platform, which is intended to support nanotechnology-enabled therapeutic delivery across multiple applications. The company’s work involving Sapu003 reflects broader industry efforts focused on improving delivery performance and therapeutic scalability through advanced formulation technologies. By concentrating on delivery optimization, Oncotelic aligns with increasing pharmaceutical interest in technologies capable of extending the utility of established oncology drugs. Platform Biotech Models Gain Momentum Another important trend reshaping biotechnology involves the emergence of scalable platform-biotech models that combine therapeutic development with enabling technologies such as artificial intelligence. Artificial intelligence is becoming increasingly important across pharmaceutical research, clinical development and biomarker analysis. AI-enhanced biomedical infrastructure may help improve development efficiency, optimize therapeutic targeting and support precision pharmacokinetic modeling. As a result, investors and pharmaceutical companies alike are showing increasing interest in biotechnology firms capable of integrating therapeutic innovation with scalable enabling technologies. Platform-based development strategies may also create opportunities for licensing partnerships and diversified commercialization pathways. Rather than depending solely on one therapeutic outcome, companies operating platform technologies may be able to support multiple therapeutic applications across oncology, rare disease and precision medicine markets. This broader scalability can potentially reduce development risk while increasing long-term strategic optionality. Once again, Oncotelic Therapeutics is pursuing this type of integrated platform strategy through both Deciparticle and PDAOAI, the company’s AI-enhanced biomedical infrastructure initiative. Together, these technologies are designed to support broader therapeutic scalability and data-driven biomedical development across oncology and rare disease indications. This positions the company at the intersection of several high-growth sectors simultaneously, including nanotechnology, oncology therapeutics and AI-enabled healthcare infrastructure. Investors Watch Multi-Application Technologies Investor attention across biotechnology is increasingly shifting toward companies developing differentiated platform technologies capable of supporting multiple drugs and therapeutic indications. Rising development costs and lengthy regulatory timelines are encouraging investors to evaluate companies not only on individual drug candidates but also on the scalability and flexibility of their underlying technologies. This trend reflects broader changes occurring across the pharmaceutical sector. Large pharmaceutical companies continue seeking opportunities to acquire or partner with smaller firms possessing scalable delivery technologies, AI-supported development infrastructure and platform-based therapeutic capabilities. Technologies capable of supporting multiple indications may offer broader long-term commercial potential than single-asset development programs alone. At the same time, the broader drug-delivery market continues expanding rapidly. Reports such as MarketsandMarkets indicated that advanced drug-delivery systems represent one of the fastest-growing areas of pharmaceutical innovation as companies prioritize improved therapeutic targeting, bioavailability and patient adherence. Investors are increasingly viewing these technologies as critical infrastructure supporting the future of precision medicine and oncology treatment. Oncotelic Therapeutics is positioning itself within this evolving market dynamic through advancement of Sapu003, Deciparticle and PDAOAI. The company’s strategy focuses on platform technologies that may support multiple therapeutic applications and future expansion opportunities rather than relying exclusively on a single drug candidate. As industry interest grows around nanotechnology-enabled delivery systems and AI-enhanced biomedical development, platform-oriented biotechnology models such as Oncotelic’s may continue attracting attention across both healthcare and investment markets. Platform Biotech Gains Strategic Momentum A growing number of life sciences and technology companies are shifting their focus from developing individual products to building scalable platforms capable of generating multiple future opportunities. Whether through advanced cell therapy infrastructure, gene therapy development engines, high-performance AI computing networks or integrated immunotherapy ecosystems, the emphasis is increasingly on creating repeatable capabilities that can support long-term growth, accelerate innovation and unlock value across multiple programs and markets. Some of these companies have made milestone announcements recently. Northwest Biotherapeutics Inc. (OTCQB: NWBO) is establishing its own dedicated clinic for leukapheresis procedures at the London Welbeck Hospital. The company, which is establishing the clinic in order to proactively address potential constraints in available leukapheresis capacity, anticipates that this move will facilitate scale-up of its programs and will enable provision of these services for other parties. A leukapheresis procedure is a specialized blood draw that is necessary to collect a patient’s immune cells for immunotherapies such as DCVax as well as CAR-Ts and other T cell therapies, and for certain other types of therapies. The buildout is expected to finish by June, and the license applications are being pursued in parallel. The first leukapheresis machine has been delivered and the initial personnel have been selected. Sangamo Therapeutics Inc. (OTCQB: SGMO) is advancing the rolling submission of a BLA to the U.S. Food and Drug Administration (“FDA”). The company is seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry disease. According to the company, following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. HIVE Digital Technologies Ltd. (NASDAQ: HIVE) is advancing a major infrastructure investment in Ontario through BUZZ High Performance Computing Inc., it’s wholly owned subsidiary. The investment is anchored by a planned new industrial-scale AI infrastructure facility, also known as an AI gigafactory, in the Greater Toronto area with approximately 320 megawatts of utility capacity. The project is expected to become one of Canada’s largest AI gigafactories, designed to support fully vertically integrated AI supercomputers and host more than 100,000 GPUs at full build-out. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is reporting positive early data from a pilot clinical trial. The trial is being led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy. Initial data indicates that, among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval. These announcement highlight a broader industry trend toward platform-driven business models that prioritize scalability, operational leverage and future optionality. As organizations continue investing in foundational capabilities that can support multiple therapies, technologies or applications, the companies best positioned to execute on these strategies may gain significant advantages in an increasingly competitive and innovation-driven landscape. For more information, visit Oncotelic Therapeutics Inc. About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com DISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com BioMedWire is powered by IBN

Immunotherapy

100 Deals associated with Lifileucel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic melanoma	Australia	Iovance Biotherapeutics, Inc.	03 Jun 2026
Unresectable Melanoma	Australia	Iovance Biotherapeutics, Inc.	03 Jun 2026
Melanoma	United States	Iovance Biotherapeutics, Inc.	16 Feb 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma, Cutaneous Malignant	Phase 2	United States	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	Australia	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	Canada	Iovance Biotherapeutics, Inc.	28 Nov 2025
Melanoma, Cutaneous Malignant	Phase 2	United Kingdom	Iovance Biotherapeutics, Inc.	28 Nov 2025
Advanced Endometrial Carcinoma	Phase 2	United States	Iovance Biotherapeutics, Inc.	29 Oct 2024
Uterine Cervical Cancer	Phase 2	United States	Iovance Biotherapeutics, Inc.	21 Mar 2022
metastatic non-small cell lung cancer	Phase 2	United States	Iovance Biotherapeutics, Inc.	07 May 2019
metastatic non-small cell lung cancer	Phase 2	Canada	Iovance Biotherapeutics, Inc.	07 May 2019
metastatic non-small cell lung cancer	Phase 2	Germany	Iovance Biotherapeutics, Inc.	07 May 2019
metastatic non-small cell lung cancer	Phase 2	Greece	Iovance Biotherapeutics, Inc.	07 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05607095 (ASCO2026)	Phase 1/2	Malignant Fibrous Histiocytoma \| Dedifferentiated Liposarcoma	10	LN-145	acrxhfyngm(ghjkfsvenb) = qhvzfmwoyg jzdyojtrfn (dkoekzndug ) View more	Positive	29 May 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Unresectable Melanoma	41	Lifileucel infusion (≤2 prior lines of therapy)	mywlhppbet(hamkcbznkx) = wddbtverxn zpdoiddeqz (eupucqydrp )	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Unresectable Melanoma	41	Lifileucel infusion (≥3 prior lines of therapy)	mywlhppbet(hamkcbznkx) = xyfcowlrrr zpdoiddeqz (eupucqydrp )	Positive	04 Feb 2026
NCT02360579 (LN-144 \| C-144–01 \| C-144-01, CTgov)	Phase 2	Metastatic melanoma	220	Lifileucel (Cohort 1)	ukpwivpgxf = aumhpclqrj cmrnhppzxj (egyoispfcd, rsmozxnauq - lcfeusrfha) View more	-	09 Dec 2025
NCT02360579 (LN-144 \| C-144–01 \| C-144-01, CTgov)	Phase 2	Metastatic melanoma	220	Lifileucel (Cohort 2)	ukpwivpgxf = wbjzltmirm cmrnhppzxj (egyoispfcd, afnmzgfpgk - hxaguokgmo) View more	-	09 Dec 2025
NCT04614103 (IOV-LUN-202, Company_Website) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma	39	Lifileucel	zmjnkpumji(nbsialyosv) = yhsomhzzld arwnakihrd (penkarolbm ) View more	Positive	03 Nov 2025
NCT02360579 (C-144-01, ESMO2025) Manual	Phase 2	Metastatic melanoma	106	Lifileucel	yzcznlwoah(tgylaoyhxa) = bijzclyikm orcldyhwnl (qvzjsbapis, 16.7 - 35.7) View more	Positive	17 Oct 2025
ESMO_IO2025	Not Applicable	Metastatic melanoma	13	Lifileucel (metastatic melanoma)	hmwqitfbfe(rbcnedqchq) = lbyqvnpdnn kyvzgpdodl (wvcftyxhbe ) View more	Positive	12 Oct 2025
NEWS Manual	Not Applicable	Melanoma	41	Amtagvi(lifileucel)	kkhpvbqxbd(lvrimeyvqc) = ajhechlxlx omxtabfjdg (zbfwslgxor )	Positive	04 Aug 2025
NEWS Manual	Not Applicable	Melanoma	41	Amtagvi (早期患者(既往≤2线治疗))	kkhpvbqxbd(lvrimeyvqc) = pxlrccrjgn omxtabfjdg (zbfwslgxor )	Positive	04 Aug 2025
NCT02360579 (C-144-01, ASCO2025) Manual	Phase 2	Melanoma	153	Lifileucel	urzdbuejkf(ylfdvoacxj) = bytyyrlzqi acgczxzpvk (rizonjenyh ) View more	Positive	30 May 2025
NCT03645928 (IOV-COM-202, SITC2024) Manual	Phase 2	metastatic non-small cell lung cancer Second line \| First line \| Third line	22	Lifileucel plus Pembrolizumab (EGFR -wt)	mkwnygjglz(xbaeuklbzj) = hmuruiqciq qqdkyequan (gzmebdhray, 35.1 - 87.2) View more	Positive	05 Nov 2024
NCT03645928 (IOV-COM-202, SITC2024) Manual	Phase 2		22	Lifileucel plus Pembrolizumab (EGFR-mutation post-TKI)	mkwnygjglz(xbaeuklbzj) = tkensxxqxp qqdkyequan (gzmebdhray )	Positive	05 Nov 2024
NCT03645928 (IOV-COM-202, Pubmed \| Cancer Discov) Manual	Phase 2	metastatic non-small cell lung cancer \| Advanced Lung Non-Small Cell Carcinoma	28	Lifileucel	mdhxekksdr(tktbarlapr) = czdeswpgvw drjnshacie (azdbzdaevz ) View more	Positive	02 Aug 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lifileucel

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation